雷替曲塞联合奥沙利铂经TACE治疗不可切除肝癌患者的疗效评价  

Transcatheter arterial chemoembolization using raltitrexed plus oxaliplatin for the treatment of inoperable primary hepatic carcinomas: evaluation of its effect

作　　者：贺红杰[1] 宋磊[1] 赵丹懿[1] 吴杰[1] 夏佩 

机构地区：[1]大连医科大学附属第二医院介入科,辽宁大连116027

出　　处：《介入放射学杂志》2016年第1期40-43,共4页Journal of Interventional Radiology

摘　　要：目的探讨雷替曲塞联合奥沙利铂经动脉化疗栓塞术(TACE)治疗不可切除肝癌患者的临床疗效和安全性。方法收集经病理检查证实或临床诊断的不可手术切除原发性肝癌患者53例,分为观察组(n=18,2013年3月—2014年4月),予雷替曲塞(3 mg/m2)联合奥沙利铂(85 mg/m2)、表柔比星10 mg行TACE治疗;对照组(n=35,2012年1月—2014年4月),予5-FU(600 mg/m2)联合DDP(40 mg/m2)、表柔比星10 mg行TACE治疗。末次随访时间为2015年4月30日。主要研究终点是中位无进展生存期(m PFS),次要终点是:1术后1个月的疗效评价;2不良反应的评价。结果观察组和对照组的m PFS分别为10.3个月、7.2个月(P=0.047),疾病有效率(RR)分别为77.8%、77.1%(P>0.05),疾病控制率(DCR)分别为94.4%、97.1%(P>0.05);两组的主要不良反应为发热、恶心呕吐、肝区疼痛、骨髓抑制及转氨酶升高等,差异均无统计学意义(P>0.05)。结论将雷替曲塞联合奥沙利铂应用到TACE治疗中可显著延长不可切除肝癌患者的无进展生存期,值得进一步研究。Objective To investigate the clinical efficacy and safety of transcatheter arterial chemoembolization （TACE） using raltitrexed plus oxaliplatin in treating inoperable primary hepatic carcinomas. Methods A total of 53 patients with pathologically- proved or clinically-confirmed inoperable primary hepatic carcinoma were collected. The patients were divided into the study group （n=18）, who were admitted to author＇s hospital during the period from March 2013 to April 2014 and were treated with TACE using raltitrexed （3 rag/m2）, oxaliplatin （85 mg/m2） and epirubicin 10 mg, and the control group （n=35）, who were admitted to author＇s hospital during the period from January 2012 to April 2014 and were treated with TACE using 5-FU （600 mg/m2）, DDP （40 mg/m2） and epirubicin 10 mg. The end of the follow-up period was April 30, 2015. The primary study endpoint was progression free survival （PFS） time, and the secondary study endpoints were （1） the evaluation of the efficacy one month after the treatment and （2） the evaluation of adverse reactions. Results The median PFS values of the study group and the control group were 10.3 months and 7.2 months respectively （P=0.047）. The response rate （RR） of the study group and the control group were 77.8% and 77.1% respectively （P〉0.05）, and the disease control rate of the study group and the control group were 94.4% and 97.1% respectively （P〉0.05）. The main adverse reactions in the two groups were fever, nausea and/or vomiting, pain in the liver region, bone marrow suppression and elevation of transaminase, but the differences between the two group s were not statistically significant （P〉0.05）. Conclusion TACE using raltitrexed plus oxaliplatin can significantly extend the progression free survival time of patients with inoperable primary hepatic carcinoma, and this technique is worth to be further studied.

关 键 词：雷替曲塞 原发性肝癌 动脉灌注化疗栓塞术 无进展生存期 

分 类 号：R735.7[医药卫生—肿瘤]